Get started
Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ARWR chart


Full chart

ARWR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.72 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.65 USD
Net income (FY)
‪−205.28 M‬ USD
Revenue (FY)
‪240.74 M‬ USD
Shares float
‪118.50 M‬
Beta (1Y)
1.54

Employees


Employees (FY)
525
Change (1Y)
+128 +32.24%
Revenue / Employee (1Y)
‪458.54 K‬ USD
Net income / Employee (1Y)
‪−391.00 K‬ USD

About Arrowhead Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher Richard Anzalone
Website
arrowheadpharma.com
Headquarters
Pasadena
Founded
1989
FIGI
BBG000BRVKH0
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ARWR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ARWR is 21.89 USD — it has increased by 2.34% in the past 24 hours. Watch Arrowhead Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arrowhead Pharmaceuticals, Inc. stocks are traded under the ticker ARWR.
ARWR stock has risen by 11.97% compared to the previous week, the month change is a 21.54% rise, over the last year Arrowhead Pharmaceuticals, Inc. has showed a −20.02% decrease.
We've gathered analysts' opinions on Arrowhead Pharmaceuticals, Inc. future price: according to them, ARWR price has a max estimate of 71.00 USD and a min estimate of 20.00 USD. Watch ARWR chart and read a more detailed Arrowhead Pharmaceuticals, Inc. stock forecast: see what analysts think of Arrowhead Pharmaceuticals, Inc. and suggest that you do with its stocks.
ARWR reached its all-time high on Dec 16, 1993 with the price of 2,924.91 USD, and its all-time low was 1.20 USD and was reached on Dec 21, 2016. View more price dynamics on ARWR chart.
See other stocks reaching their highest and lowest prices.
ARWR stock is 4.38% volatile and has beta coefficient of 1.54. Track Arrowhead Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arrowhead Pharmaceuticals, Inc. there?
Today Arrowhead Pharmaceuticals, Inc. has the market capitalization of ‪2.72 B‬, it has decreased by −1.10% over the last week.
Yes, you can track Arrowhead Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Arrowhead Pharmaceuticals, Inc. is going to release the next earnings report on Nov 26, 2024. Keep track of upcoming events with our Earnings Calendar.
ARWR earnings for the last quarter are −1.38 USD per share, whereas the estimation was −0.53 USD resulting in a −160.91% surprise. The estimated earnings for the next quarter are −0.97 USD per share. See more details about Arrowhead Pharmaceuticals, Inc. earnings.
Arrowhead Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪52.87 M‬ USD. In the next quarter, revenue is expected to reach ‪55.07 M‬ USD.
ARWR net income for the last quarter is ‪−170.79 M‬ USD, while the quarter before that showed ‪−125.30 M‬ USD of net income which accounts for −36.31% change. Track more Arrowhead Pharmaceuticals, Inc. financial stats to get the full picture.
No, ARWR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 525.00 employees. See our rating of the largest employees — is Arrowhead Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arrowhead Pharmaceuticals, Inc. EBITDA is ‪−529.78 M‬ USD, and current EBITDA margin is −79.97%. See more stats in Arrowhead Pharmaceuticals, Inc. financial statements.
Like other stocks, ARWR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arrowhead Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arrowhead Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arrowhead Pharmaceuticals, Inc. stock shows the sell signal. See more of Arrowhead Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.